Member Info for D-Geeman

Trouble is, and it only takes seconds to go back through history to page 50 from page 2, Cindercone is not blessed with sound judgement;

'Retrospect15 Apr 2021 15:50

In retrospect 'big Al' should have been a lot more open-ended when it came to expressing timescales, i.e. only give timescales for things you can control, not what third-parties are in control of - especially UK govt. Like many CEOs he didn't really think about how the minutiae of his words would be perceived by AIM's investor asylum.

Ultimately, it changes nothing. Either the well-researched and patient will be handsomely rewarded and the AIM gimps will drown in regret or AVCT is utterly incompetent. I refuse to entertain the latter, which will have far reaching consequences for other arms of the business in terms of lack of investor confidence.'

No need to remind you what Wyn was was speculating at the time even though it tends to get airbrushed out of people's recollections when they post he's never been right about anything.

'did you have a good day yesterday D?'

Just to elaborate Wyn, and she didn't want to repeat this yesterday I sensed, the UK folk are a lot less helpful so they are avoided by doing things this way.

Oddly enough Wyn, I might have some ‘info’ here wyn :-)

Only relatively inside though.

At Science Day CC explained to 3 or 4 of us how good comms were with the FDA. Great even. Draw from that what you will.

I don’t think surprises are quite as likely as they used to be...

Morning Wyn, to be fair to CC she has kept to time with all her deadlines I believe.

Scancell down quite a bit as I write. People on the BB there speculating it's partly down to the highlighted issues of raising money on AIM and ‘forcing’ move to Nasdaq. That, and waiting for news..

And as confirmed by the Business News article (did you read it Yeboha?) Avct have cash until *early* Q1

Rather than developing a new generation that has 3, 4, 5 payloads, couldn't they just infuse Gen 1 and Gen 2 or 3 at the same time to deliver 3 or 4 warheads.

Is Gen 3 to prove the versatility of the platform as Avct won't actually do it all themselves.

FAO Met and Yeboha, from someone who was only able to give the presentation passing attention:

'AI Overview

Avacta's cash runway extends into early Q1 2027.

The company significantly strengthened its financial position by raising £32.5 million over the past 18 months, including an oversubscribed £10 million share placing and subscription in March 2026. This liquidity ensures operations are funded past key clinical and commercial milestones.'

(No need to apologise, and no accusations from me of bending the truth to an agenda, simply a case I think of not hearing every detail, even important ones.)

‘ DG doesn't pay full attention’

Yep, daughter’s GCSEs trump my portfolio’s performance, especially when she is having problems despite school and exam board’s allowances.

Except Yeboha, and I said I wasn’t 100% able to listen, was she said “early Q1” and since Q1 is Jan / Feb / March, I would not say March is early. And I think yoy would have got more reccs had your understanding been correct and mine (and wyn’s) wrong.

'No one gives a flying.. ‘

Clearly not true wyn, and I’d green box CJ but some of his 'pre-lunch' posts make more sense.

You keep going with your sober thinking on avct.

'cash run away is to early 2027 which could be all the way up the March 2027'

I wasn't paying 100% attention but I thought she said "to early Q1 2027" so March would not fit that.

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tue, 19 May 2026 at 12:00 pm BST 6 min read

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated clinical data from its ongoing Expanded Access ("EA") Program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The data, updated from March 2025 to as of March 2026, demonstrate that intranasal foralumab continues to be extremely well tolerated over extended treatment durations. Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale (EDSS) and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale (MFIS).

https://uk.finance.yahoo.com/news/tiziana-announces-positive-clinical-data-110000198.html

Chai, interesting. I did wonder about this a couple of days ago. Here's a new search;

'These are results for are institutional investors more likely to invest in a company with a market cap bigger than £400m'

AI Overview

Yes, institutional investors are significantly more likely to invest in a company with a market cap over £400m compared to smaller companies.

Institutional investors (such as pension funds, insurance companies, and mutual funds) have strict mandates requiring liquidity and safety, which are generally found in larger companies, often referred to as mid-cap or large-cap.

Here is why a market cap above £400m (roughly ~$500m+) makes a company more attractive to institutions:

1. Increased Liquidity (Easier Buying/Selling)

Large Positions: Institutions manage huge sums of money and buy or sell in large "block trades" (often 10,000+ shares).

Liquidity Risk: In smaller companies (often below £200m–£400m), buying or selling large blocks of shares can severely move the price against them, increasing costs.

Thresholds: A market cap over £400m often guarantees a higher "[free float]"—the percentage of shares freely available for trading—making it easier for them to enter and exit positions without affecting the share price.

2. Risk Management and Mandates

Stability: Large-cap and mid-cap companies generally have greater financial reserves, higher stability, and are less volatile than small-caps.

Mandate Restrictions: Many institutional funds have minimum market capitalization requirements in their investment mandates to prevent them from taking on too much risk.

Liquidity Pressure: Institutional fund managers are under pressure to invest in larger, more liquid stocks to meet redemptions, especially during market volatility.

3. Visibility and Information Availability

Analyst Coverage: Companies with a higher market cap receive more attention from equity researchers and financial analysts.

Reduced Risk: Better information availability reduces the risk of sudden, nasty surprises, which is crucial for institutional investors.

Mrs CJ: "That's all very well CJ but being on your phone with friends is extremely rude you know."

CJ: "That's OK sweetness, I was on my own just drinking.. Two hours before KO...

By the way, I fancy a new car when I get my licence back. A Ford Pubic. Made of old Corsairs :-) Would suit my obsession perfectly!"

CJ in Rise and Fall of Reginald Perrin, episode 5 (series two).

Mrs CJ: "I'm home darling, how was your drink and football over the weekend? And how's the ex? Did you catch up?"

CJ: "Well sweetness. Apparently a great game of football and seeing people would've been nice but time completely ran away with me. I was on a bulletin board arguing with enemies instead".

‘

If you struggle with binge drinking on the weekends, Confidant Health’s online alcohol rehab can help you reclaim your weekends for healthy, nourishing activities instead. Our medication-assisted treatment for alcohol use provides you with the resources you need to minimize withdrawal symptoms and address triggers for weekend drinking. Download our app today to learn more.

People also ask

How to stop binge drinking at weekends?

Always have something to eat first. Have a non-alcoholic drink, like water or a soft drink, between each alcoholic one. Try switching to lower alcohol drinks, and drink slower. Try changing your social habits – pick a new hobby to work on, or make plans to go out and do things that don't involve drinking.‘

Bump:

‘cj62

9 May 2026 12:27

“I nearly spit my beer out”

That’s 12.27pm Touk, lunchtime. And yet fixated on your supposed 🍷. Takes all sorts doesn’t it 😂

Enjoy your hols!

'No Edam in evidence'

I'll check the north coast in late July when we stay in Boscastle.

Perhaps of interest to TOUK https://www.bbc.co.uk/sounds/play/m002v9kf (The Reunion / Eden project)

Perhaps of interest to BV https://www.bbc.co.uk/sounds/play/m0002mfr (Mark Steele / in Malta)

Https://uk.finance.yahoo.com/news/tiziana-reports-reduced-brain-inflammation-110000805.html

Tiziana Life Sciences Ltd.

Thu, 14 May 2026 at 12:00 pm BST 6 min read

TLSA

-3.85%

Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd.

Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy

BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.

Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to be affected in MSA following treatment with intranasal foralumab. In the first two treated patients, investigators observed up to approximately 35% reduction in standardized uptake value (SUV) and approximately 24% reduction in standardized uptake value ratio (SUVR) in affected areas of the brain.

Significant reduction in basal ganglia and thalamic uptake following nasal foralumab

The reductions were observed in regions including the basal ganglia and cerebellar white matter, which are known to be involved in the neurodegenerative processes underlying MSA.

“These early PET imaging findings provide quantitative evidence supporting the biological activity of intranasal foralumab in patients with MSA,” said Tarun Singhal, MBBS, M.D., Founding Director, NeuroPET Program, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Mass General Brigham. “In the first two MSA patients we evaluated, we observed up to approximately 35% reduction in standardized uptake value and a 24% reduction in SUV ratio in the affected brain regions. We focused on the most severely affected, clinically relevant areas known to be involved in MSA. Based on the available data, these appear to be robust quantitative findings and are comparable to results previously observed in patients with multiple sclerosis treated with intranasal foralumab, although there are methodological differences.”